BEST OF HEMATOLOGY 2024: Bristol Myers Squibb Breakfast Symposium: Commanding the Management of LR MDS – Dr. Guillermo Garcia-Manero & Dr. James Kennedy
OR
Chair
Dr. Martina Trinkaus
Dr. Matthew Seftel
Panelist
Dr. Guillermo Garcia-Manero
Dr. James Kennedy
This program has been made possible through unrestricted support from Bristol Myers Squibb
Studies/trials discussed:
- A prognostic score for patients with lower risk myelodysplastic syndrome
- A pilot pharmacokinetic study of oral azacitidine
- Clinical and biological implications of driver mutations in myelodysplastic syndromes
- Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management
- Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
- Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
- Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management
- Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome
- Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis
- Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis
- Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
- Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial
- COMMANDS: Study Design
- A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
- Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial
- Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS
- Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine
- Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA)
- Durable Clinical Benefit with Ker-050 Treatment: Findings from an Ongoing Phase 2 Study in Participants with Lower-Risk MDS
- A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS
